Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Is AgEagle Aerial Systems a Buy Under $3?

By Will Ashworth, InvestorPlace Contributor

AgEagle Aerial Systems has fallen back to earth so far in September with UAVS stock down 8% through Sep. 16. Is it a buy under $3?

Tesla or Nio: Which of the Two High Flyers Will Win the 2020 Horse Race?

By Will Ashworth, InvestorPlace Contributor

esla and Nio are in a horse race in 2020. With three-and-a-half months left in the year, can Nio stock outperform Elon Musk and company? 

Why Aurora Cannabis’ New CEO Ought to Be Good for Shareholders

By Will Ashworth, InvestorPlace Contributor

Aurora Cannabis promoted Miguel Martin to chief executive officer on Sep. 8. Here’s why that’s a good thing for ACB stock. 

Trading Under $10, Tilray Stock Could Still Tick Back Up To $20

By Will Ashworth, InvestorPlace Contributor

Tilray’s been on a wild ride in 2020. At one point, Tilray stock was trading over $20. Having lost 75% of its value, is there any hope left?

Is Lemonade Stock a Buy Over $50?

By Will Ashworth, InvestorPlace Contributor

Lemonade delivered second-quarter results in mid-August. They missed the mark. Down 22% since, I’m wondering if Lemonade stock is a buy.  

The Latest Correction Makes Square Stock a Good Buy for the Long Haul

By Will Ashworth, InvestorPlace Contributor

In the latest mini-correction of tech stocks, Square has seen its shares lose their momentum. If you own SQ stock, it’s time to buy more.

Novavax’s Run to $200 by the End of 2020 Is Looking Less Likely 

By Will Ashworth, InvestorPlace Contributor

Novavax signed an agreement with the Canadian government for its potential Covid-19 vaccine Aug. 31. NVAX stock has been falling ever since.

Sorrento Therapeutics Is a Scary, Risky Potential Buy

By Will Ashworth, InvestorPlace Contributor

Sorrento Therapeutics has lost 44% since firing its chief financial officer on Aug. 19. Is SRNE stock a buy given its drop in recent days?

Here’s Why IBIO’s Choice of IBIO-201 in the Vaccine Race is a Good Thing

By Will Ashworth, InvestorPlace Contributor

Ibio recently announced IBIO-201 as its coronavirus vaccine candidate. Despite a long road ahead, it’s good news for IBIO stock.   

Hertz Stock Could Survive Bankruptcy. Does Anybody Care?

By Will Ashworth, InvestorPlace Contributor

Could Hertz shareholders face a similar fate to Whiting Petroleum? If so, should you be buying Hertz stock at current prices? 

Load More